Display options
Cite
Farhangian ME, Huang WW, Feldman SR. Adherence to Oral and Topical Medications in Cutaneous Lupus Erythematosus is not Well Characterized. Dermatol Ther (Heidelb). 2015;5(2):91-105doi: 10.1007/s13555-015-0075-4.
Farhangian, M. E., Huang, W. W., & Feldman, S. R. (2015). Adherence to Oral and Topical Medications in Cutaneous Lupus Erythematosus is not Well Characterized. Dermatology and therapy, 5(2), 91-105. https://doi.org/10.1007/s13555-015-0075-4
Farhangian, Michael E, et al. "Adherence to Oral and Topical Medications in Cutaneous Lupus Erythematosus is not Well Characterized." Dermatology and therapy vol. 5,2 (2015): 91-105. doi: https://doi.org/10.1007/s13555-015-0075-4
Farhangian ME, Huang WW, Feldman SR. Adherence to Oral and Topical Medications in Cutaneous Lupus Erythematosus is not Well Characterized. Dermatol Ther (Heidelb). 2015 Jun;5(2):91-105. doi: 10.1007/s13555-015-0075-4. Epub 2015 Apr 22. PMID: 25899142; PMCID: PMC4470959.
Copy Download .nbib Format: NLM
Share it on

Dermatol Ther (Heidelb). 2015 Jun;5(2):91-105. doi: 10.1007/s13555-015-0075-4. Epub 2015 Apr 22.

Adherence to Oral and Topical Medications in Cutaneous Lupus Erythematosus is not Well Characterized.

Dermatology and therapy

Michael E Farhangian, William W Huang, Steven R Feldman

Affiliations

  1. Department of Dermatology, Center for Dermatology Research, Wake Forest School of Medicine, Winston-Salem, NC, USA, [email protected].

PMID: 25899142 PMCID: PMC4470959 DOI: 10.1007/s13555-015-0075-4

Abstract

INTRODUCTION: Treatment adherence plays a large role in chronic dermatologic diseases and may play an important role in the outcomes of patients with cutaneous lupus erythematosus (CLE). We sought to gauge what is currently known about adherence to topical and oral medications in patients with CLE.

METHODS: A review of MEDLINE was performed using a combination of the phrases "adherence", "compliance", "lupus", and "cutaneous". Studies were hand searched and prospective and cross-sectional studies evaluating medication adherence in patients with CLE and systemic lupus erythematosus (SLE) were included.

RESULTS: Only two articles explored adherence in patients with CLE, while 17 articles discussed treatment adherence in patients with SLE. Depression was consistently cited as detrimental to adherence. The impact that race, ethnicity, and education has on adherence is unclear. Three studies noted a clear connection between adherence and disease activity, while two others did not. Few studies investigated methods that have improved adherence to treatment which have showed promise.

CONCLUSION: Much of what we know about adherence to medication in patients with lupus is limited to SLE. Although cutaneous symptoms are among the most common manifestations of SLE, cutaneous disease is often managed at least in part with topical agents, and adherence to topical treatment was not assessed in any of the articles, though one study investigated sunscreen usage in patients with CLE. Understanding adherence in patients with CLE may help contribute to better CLE treatment outcomes.

References

  1. Arthritis Rheum. 1997 Sep;40(9):1725 - PubMed
  2. Best Pract Res Clin Rheumatol. 2013 Jun;27(3):329-40 - PubMed
  3. Rheumatology (Oxford). 2009 Mar;48(3):266-71 - PubMed
  4. Compr Psychiatry. 2007 Jan-Feb;48(1):14-9 - PubMed
  5. Am J Clin Dermatol. 2014 Apr;15(2):87-94 - PubMed
  6. Br J Dermatol. 2015 Sep;173(3):831-4 - PubMed
  7. Actas Dermosifiliogr. 2013 Jun;104(5):409-17 - PubMed
  8. J Rheumatol. 2012 Jan;39(1):174-9 - PubMed
  9. Arch Dermatol. 2012 Apr;148(4):479-84 - PubMed
  10. Hypertens Res. 2008 Nov;31(11):2037-43 - PubMed
  11. Rheumatol Int. 2015 Jun;35(6):1045-51 - PubMed
  12. Lupus. 2011 Jan;20(1):14-22 - PubMed
  13. J Am Acad Dermatol. 2004 Aug;51(2):212-6 - PubMed
  14. Semin Cutan Med Surg. 2010 Jun;29(2):137-40 - PubMed
  15. N Engl J Med. 2005 Aug 4;353(5):487-97 - PubMed
  16. Br J Dermatol. 2014 Feb;170(2):315-21 - PubMed
  17. Arthritis Care Res (Hoboken). 2011 Mar;63(3):342-50 - PubMed
  18. J Eur Acad Dermatol Venereol. 2014 May;28 Suppl 2:4-9 - PubMed
  19. Lupus. 2008 Aug;17(8):761-9 - PubMed
  20. J Clin Cell Immunol. 2014 Jun;5(3):null - PubMed
  21. J Clin Rheumatol. 2008 Aug;14(4):195-201 - PubMed
  22. Curr Rheumatol Rep. 2011 Aug;13(4):300-7 - PubMed
  23. Arthritis Rheum. 2002 Dec 15;47(6):630-8 - PubMed
  24. Eur J Dermatol. 2014 May-Jun;24(3):385-6 - PubMed
  25. Lupus. 2012 Oct;21(11):1158-65 - PubMed
  26. Clin Exp Dermatol. 2012 Jun;37(4):327-34 - PubMed
  27. Arthritis Rheum. 2007 Aug 15;57(6):1000-6 - PubMed
  28. Patient Educ Couns. 2011 Oct;85(1):53-9 - PubMed
  29. Br J Dermatol. 2013 Jan;168(1):20-31 - PubMed
  30. Clin Dermatol. 2006 Sep-Oct;24(5):348-62 - PubMed
  31. Lupus. 2007;16(9):701-6 - PubMed
  32. Ann Rheum Dis. 2007 Jun;66(6):821-4 - PubMed
  33. Arthritis Rheum. 2006 Oct;54(10):3284-90 - PubMed
  34. J Am Acad Dermatol. 1999 Oct;41(4):581-3 - PubMed
  35. Dermatology. 2000;200(4):292-8 - PubMed
  36. J Am Acad Dermatol. 2006 May;54(5 Suppl):S235-6 - PubMed
  37. Arthritis Rheum. 2009 Feb 15;61(2):240-6 - PubMed
  38. Lupus. 2011 Mar;20(3):320-9 - PubMed
  39. JAMA. 2002 Jul 24-31;288(4):455-61 - PubMed

Publication Types